Early research (Phase 1)Study completedNCT05990920
What this trial is testing
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
Who this might be right for
Pathologically Confirmed Cancer Refractory to Conventional TherapyRefractory CancerMetastatic Cancer+5 more
NKGen Biotech, Inc. 6